Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer

Annals of Oncology

Volumn 16, Issue 8, 2005, Pages 1305-1310

  Negri, F V ^a   Wotherspoon, A ^a   Cunningham, David ^a   Norman, A R ^a   Chong, G ^a   Ross, P J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

5 fluorouracil; Colorectal cancer; Mucinous

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 23844521660     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi244     Document Type: Article

References (32)

1. Parham D. Colloid carcinoma. Ann Surg 1923; 77: 90-105.
2. AJCC Cancer Staging Manual, 6th edition. New York: Springer 2002.
3. Symonds DA, Vickery AL. Mucinous carcinoma of the colon and rectum. Cancer 1976; 37: 1891-1900.
4. Nissan A, Guillem JG, Paty PB et al, Signet-ring cell carcinoma of the colon and rectum: A matched control study. Dis Colon Rectum 1999; 42: 1176-1180.
5. Odone V, Chang L, Caces J et al. The natural history of colorectal carcinoma in adolescents. Cancer 1982; 49: 1716-1720.
6. Umpleby HC, Ranson DL, Williamson RC. Peculiarities of mucinous colorectal carcinoma. Br J Surg 1985; 72: 715-718.
7. Hanski C, Tiecke F, Hummel M et al. Low frequency of p53 gene mutation and protein expression in mucinous colorectal carcinomas. Cancer Lett 1996; 103: 163-170.
8. Lanza G Jr, Maestri I, Dubini A et al. p53 expression in colorectal cancer: Relation to tumor type, DNA ploidy pattern and short-term survival. Am J Clin Pathol 1996; 105: 604-612.
9. Messerini L, Vitelli F, De Vitis LR et al. Microsatellite instability in sporadic mucinous colorectal carcinomas: Relationship to clinicopathological variables. J Pathol 1997; 182: 380-384.
10. Bazan V, Migliavacca M, Zanna I et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002; 13: 1438-1446.
11. Suma KS, Nirmala V. Mucinous component in colorectal carcinoma - prognostic significance: A study in a south Indian population. J Surg. Oncol 1992; 51: 60-64.
12. De Mascarel A, Coindre JM, de Mascarel I et al. The prognostic significance of specific histologic features of carcinoma of the colon and rectum. Surg Gynecol Obstet 1981; 153: 511-514.
13. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
14. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
15. Hill M, Norman A, Cunningham D et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 1995; 13: 2317-2323.
16. Ross P, Norman A, Cunningham D et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8: 995-1001.
17. Price TJ, Ross PJ, Hickish T et al. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer 2004; 3: 235-242.
18. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization 1979; Publication No. 48.
19. Minsky BD, Mies C, Rich TA et al. Colloid carcinoma of the colon and rectum. Cancer 1987; 60: 3103-3112.
20. Meyers M, Wagner MW, Hwang HS et al. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61: 5193-5201.
21. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
22. Hanski C. Is mucinous carcinoma of the colorectum a distinct genetic entity? Br. J Cancer 1995; 72: 1350-1356.
23. Ho SB, Niehans GA, Lyftogt C et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993; 53: 641-651.
24. Hanski C, Hofmeier M, Schmitt-Graff A et al. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol 1997; 182: 385-391.
25. Laurent-Puig P, Olschwang S, Delattre O et al. Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. Int. J Cancer 1991; 49: 220-223.
26. Hedrick L, Cho KR, Fearon ER et al. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 1994; 8: 1174-1183.
27. Costa A, Marasca R, Valentinis B et al. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 1995; 176: 45-53.
28. Marchetti A, Buttitta F, Pellegrini S et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993; 53: 4665-4669.
29. Milner BJ, Allan LA, Eccles DM et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-2132.
30. Hoshi T, Imai M, Ogawa K. Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. J Surg Oncol 1994; 55: 84-91.
31. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-1044.
32. Leteurtre E, Gouyer V, Rousseau K et al. Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell 2004; 96: 145-151.